Personalis Inc (PSNL)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Personalis Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 1 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 12.70 $ — 73% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 2.3% failed
- More than 10% revenue growth is expected for the coming year 41.0% passed
- Share count grows by less than 3% a year 25.0% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -131.8% failed
- Gross margin at 40% or higher and without meaningful erosion -77.4% failed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 200 m net cash passed
- Operating cash flow covers the profits of the last three years 95 m failed
- Return on capital at 15% or higher, or up versus two years ago -29.9% failed
- Insiders hold at least 10% or are net buyers 27.1% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Analysts & Price Target
The price target sits 9.3% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 7
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -1.03 | -1.07 – -1.00 | 79 | -12.7% | 7 |
| 12/31/2027 | -0.91 | -1.04 – -0.78 | 109 | 11.6% | 7 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.25 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.16 | – | 17 | -14.60 | -97.80 | -8 | -9 |
| 2025: Q1 | -0.15 | – | 21 | 5.50 | -76.40 | -18 | -21 |
| 2025: Q2 | -0.19 | – | 17 | -23.80 | -116.60 | -13 | -13 |
| 2025: Q3 | -0.21 | – | 15 | -43.60 | -149.40 | -22 | -23 |
| 2025: Q4 | -0.23 | – | 17 | 3.20 | -137.30 | -22 | -22 |
| 2026: Q1 | -0.29 | – | 16 | -24.90 | -194.10 | -23 | -26 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2017 | 9 | -22 | -24 | -1.08 | 0 | -93 | 34 |
| 2018 | 38 | -14 | -20 | -0.91 | 6 | -106 | 42 |
| 2019 | 65 | -22 | -25 | -1.39 | -18 | 107 | 157 |
| 2020 | 79 | -42 | -41 | -1.20 | -43 | 195 | 245 |
| 2021 | 85 | -65 | -65 | -1.49 | -71 | 310 | 397 |
| 2022 | 65 | -116 | -113 | -2.48 | -70 | 218 | 293 |
| 2023 | 73 | -110 | -108 | -2.25 | -56 | 129 | 225 |
| 2024 | 85 | -68 | -81 | -1.37 | -45 | 203 | 270 |
| 2025 | 70 | -88 | -81 | -0.91 | -75 | 261 | 334 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Personalis, Inc. entwickelt, vermarktet und verkauft fortschrittliche genomische Krebstests und -dienstleistungen in den USA und international.
| Employees | 259 |
|---|---|
| Headquarters | Fremont, CA |
| Address | 6600 Dumbarton Circle, 94555 Fremont, United States |
| Phone | 650 752 1300 |
| Website | personalis.com |
| IPO Date | 20. Jun 2019 |
| ISIN | US71535D1063 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Christopher M. Hall | CEO & Director | 1969 |
| Aaron L. Tachibana | CFO & COO | 1961 |
| Russ B. Altman M.D., Ph.D. | Co-Founder and Member of Clinical & Scientific Advisory Board | – |
| Euan Angus Ashley DPHIL, FRCP, M.D., Ph.D. | Co-Founder and Member of Clinical & Scientific Advisory Board | 1971 |
| Michael P. Snyder Ph.D. | Co-Founder and Member of Clinical & Scientific Advisory Board | – |
| Ashish Kheterpal | Senior VP & Chief Information Officer | – |
| Stephen M. Moore J.D. | Senior VP, Chief Legal Officer & Corporate Secretary | 1972 |
| Christian Haudenschild Ph.D. | Senior Vice President of Genomic Science | – |
| Stephane Mouradian Ph.D. | Senior Vice President of Business Development | – |
| Deepshikha Bhandari | Senior Vice President of Regulatory, Quality & Clinical Compliance | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 15. Jul 2026 | Chen Richard | President and CMO | Sell | 100,000 | 15.15 | 1,515,000 |
| 15. Jul 2026 | Chen Richard | President and CMO | Other | 100,000 | 2.44 | 244,000 |
| 9. Jul 2026 | Hall Christopher M | Chief Executive Officer | Sell | 100,000 | 15.08 | 1,508,000 |
| 9. Jul 2026 | Hall Christopher M | Chief Executive Officer | Other | 100,000 | 1.61 | 161,000 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.